Esophageal cancer · 16 regimens
Cost vs Efficacy · 5 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and Fluorouracil (CF) and Pembrolizumab Variant #01 | — | R 83 223 | 21d | — | 12.4 mo | 35 | R 2 876 965 PFS proxy | 2 |
mFOLFOX6 and Cetuximab Variant #03 | — | R 57 509 | 14d | ~8.2 mo | ~30.9 mo | ~3 | ~R 87 490 PFS proxy · indirect | 4 |
LdCF Variant #01 | — | R 8 537 | 14d | — | 12.1 mo | 2 | R 17 074 PFS proxy | 1 |
MCF Variant #01 | — | R 5 019 | 42d | — | 8.5 mo | 5 | R 25 094 PFS proxy | 1 |
Docetaxel and Irinotecan Variant #01 | — | R 3 804 | 21d | — | — | ~2 | ~R 7 608 indirect | — |
FULV and Gemcitabine Variant #02 | — | R 3 787 | 21d | — | — | ~2 | ~R 7 575 indirect | — |
EOX Variant #01 | — | R 3 772 | 21d | — | 11.3 mo | 9 | R 31 213 PFS proxy | 1 |
EOF Variant #01 | — | R 3 582 | 21d | — | ~48.0 mo | ~8 | ~R 28 660 PFS proxy · indirect | 1 |
ECX Variant #01 | — | R 2 632 | 21d | ~4.2 mo | ~30.6 mo | ~3 | ~R 7 896 PFS proxy · indirect | 6 |
ECF Variant #01 | — | R 2 442 | 21d | — | 9.4 mo | 6 | R 14 655 PFS proxy | — |
Cisplatin and Irinotecan (IC) Variant #01 | — | R 1 795 | 21d | ~3.8 mo | ~13.9 mo | ~3 | ~R 5 386 PFS proxy · indirect | 2 |
Cisplatin and Paclitaxel (TP) Variant #02 | — | R 1 315 | 21d | ~5.6 mo | ~11.1 mo | ~7 | ~R 9 204 PFS proxy · indirect | 8 |
Cisplatin and Fluorouracil (CF) Variant #01 | — | R 1 235 | 28d | — | 9.8 mo | 6 | R 7 412 PFS proxy | 2 |
Carboplatin and Paclitaxel (CP) Variant #02 | — | R 1 025 | 21d | ~7.4 mo | ~27.5 mo | ~9 | ~R 9 222 PFS proxy · indirect | 3 |
Paclitaxel monotherapy Variant #02 | — | R 734 | 28d | — | 9.2 mo | 6 | R 4 406 PFS proxy | 1 |
Best supportive care Partial | — | — | — | — | 4.2 mo | — | — | 1 |
16 of 16 regimens shown